SC
MRNS

Steven Cohen’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Steven Cohen’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-491,617
Closed -$4.44M – 2590
2024
Q1 		$4.44M Sell
491,617
-1,783
-0.4% -$17.3K 0.01% 999
2023
Q4 		$5.36M Sell
493,400
-571,637
-54% -$4.28M 0.01% 895
2023
Q3 		$8.57M Sell
1,065,037
-260,144
-20% -$2.16M 0.03% 707
2023
Q2 		$14.4M Sell
1,325,181
-1,827,819
-58% -$15.7M 0.04% 482
2023
Q1 		$21.8M Sell
3,153,000
-362,000
-10% -$2.27M 0.07% 336
2022
Q4 		$14M Buy
+3,515,000
New +$17.3M 0.05% 444
2020
Q4 		– Sell
-75,000
Closed -$964K – 1194
2020
Q3 		$964K Buy
+75,000
New +$647K ﹤0.01% 783
2018
Q4 		– Sell
-16,750
Closed -$670K – 1274
2018
Q3 		$670K Buy
+16,750
New +$477K ﹤0.01% 905
2016
Q1 		– Sell
-51,189
Closed -$1.56M – 880
2015
Q4 		$1.56M Sell
51,189
-6,785
-12% -$199K 0.01% 574
2015
Q3 		$1.93M Sell
57,974
-776
-1% -$43.8K 0.02% 567
2015
Q2 		$2.73M Buy
+58,750
New +$2.19M 0.02% 540

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Steven Cohen's MRNS Position: Q2 2024 in Review

Steven Cohen sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 491,617 shares — an estimated $4.44M sold.

Steven Cohen first reported a position in MRNS in Q2 2015 and held it in 11 quarters. The position peaked at $21.8M in Q1 2023. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Steven Cohen reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Steven Cohen sold 491,617 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $4.44M.
  • Steven Cohen first reported a position in Marinus Pharmaceuticals, Inc in Q2 2015 and held it in 11 quarters.
  • Steven Cohen's Marinus Pharmaceuticals, Inc position peaked at $21.8M in Q1 2023.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Point72 Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.